Dr Leilei Wang, MD, PHD in Bellevue, WA - Medicare Physical Medicine And Rehabilitation

Dr Leilei Wang, MD, PHD is a medicare enrolled "Specialist" physician in Bellevue, Washington. She went to University Of Pittsburgh School Of Medicine and graduated in 1990 and has 34 years of diverse experience with area of expertise as Physical Medicine And Rehabilitation. She is a member of the group practice The Association Of University Physicians and her current practice location is 14817 Se 50th St, Bellevue, Washington. You can reach out to her office (for appointments etc.) via phone at (425) 643-3259.

Dr Leilei Wang is licensed to practice in Washington (license number MD32124) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1801015029.

Contact Information

	Dr Leilei Wang, MD, PHD
	14817 Se 50th St, Bellevue, WA 98006-3507
	(425) 643-3259
	Not Available

Physician's Profile

Full Name	Dr Leilei Wang
Gender	Female
Speciality	Physical Medicine And Rehabilitation
Experience	34 Years
Location	14817 Se 50th St, Bellevue, Washington
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Leilei Wang attended and graduated from University Of Pittsburgh School Of Medicine in 1990

NPI Data:

NPI Number: 1801015029
Provider Enumeration Date: 04/25/2007
Last Update Date: 06/24/2019

Medicare PECOS Information:

PECOS PAC ID: 5597864843
Enrollment ID: I20070627000256

Medical Identifiers

Medical identifiers for Dr Leilei Wang such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1801015029	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208100000X	Physical Medicine & Rehabilitation	MD00032124 (Washington)	Secondary
174400000X	Specialist	MD32124 (Washington)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Harborview Medical Center	Seattle, WA	Hospital
University Of Washington Medical Ctr	Seattle, WA	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
The Association Of University Physicians	0446162697	3009

News Archive

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

Maxygen's option and licensing arrangement with Cangene expires

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation has expired. Under the agreement, Maxygen had granted Cangene an option to obtain an exclusive license to Maxygen's proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome.

Scarring prevents precipitous decline in heart function after cardiac injury

After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the walls of the heart, lessen its ability to pump blood throughout the body and eventually lead to heart failure. But new research from the University of North Carolina at Chapel Hill School of Medicine shows that interrupting this process can weaken heart function even further.

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe.

Heparin promotes food intake and body weight gain in animal models

Heparin is a medication widely used to prevent blood clotting; it is named after and mimics the naturally occurring anticoagulant in the body.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Leilei Wang allows following entities to bill medicare on her behalf.

Entity Name	The Association Of University Physicians
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244

News Archive

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Maxygen's option and licensing arrangement with Cangene expires

Scarring prevents precipitous decline in heart function after cardiac injury

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Heparin promotes food intake and body weight gain in animal models

Heparin is a medication widely used to prevent blood clotting; it is named after and mimics the naturally occurring anticoagulant in the body.

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Leilei Wang is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Leilei Wang, MD, PHD 14817 Se 50th St, Bellevue, WA 98006-3507 Ph: () -	Dr Leilei Wang, MD, PHD 14817 Se 50th St, Bellevue, WA 98006-3507 Ph: (425) 643-3259

News Archive

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Maxygen's option and licensing arrangement with Cangene expires

Scarring prevents precipitous decline in heart function after cardiac injury

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Heparin promotes food intake and body weight gain in animal models

Heparin is a medication widely used to prevent blood clotting; it is named after and mimics the naturally occurring anticoagulant in the body.

Dr Leilei Wang, MD, PHD - Medicare Physical Medicine And Rehabilitation in Bellevue, WA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Maxygen's option and licensing arrangement with Cangene expires

Scarring prevents precipitous decline in heart function after cardiac injury

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Heparin promotes food intake and body weight gain in animal models

Medicare Reassignments

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Maxygen's option and licensing arrangement with Cangene expires

Scarring prevents precipitous decline in heart function after cardiac injury

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Heparin promotes food intake and body weight gain in animal models

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Maxygen's option and licensing arrangement with Cangene expires

Scarring prevents precipitous decline in heart function after cardiac injury

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Heparin promotes food intake and body weight gain in animal models